These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
472 related articles for article (PubMed ID: 22066978)
1. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Koss MJ; Pfister M; Rothweiler F; Michaelis M; Cinatl J; Schubert R; Koch FH Acta Ophthalmol; 2012 Mar; 90(2):e98-e103. PubMed ID: 22066978 [TBL] [Abstract][Full Text] [Related]
2. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Noma H; Funatsu H; Mimura T; Harino S; Hori S Ophthalmology; 2009 Jan; 116(1):87-93. PubMed ID: 19118700 [TBL] [Abstract][Full Text] [Related]
3. Association of inflammatory factors with macular edema in branch retinal vein occlusion. Noma H; Mimura T; Eguchi S JAMA Ophthalmol; 2013 Feb; 131(2):160-5. PubMed ID: 23411880 [TBL] [Abstract][Full Text] [Related]
4. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema. Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239 [TBL] [Abstract][Full Text] [Related]
5. Pentraxin 3 and other inflammatory factors in central retinal vein occlusion and macular edema. Noma H; Mimura T; Masahara H; Shimada K Retina; 2014 Feb; 34(2):352-9. PubMed ID: 23842103 [TBL] [Abstract][Full Text] [Related]
6. Cytokine Kinetics after Monthly Intravitreal Bevacizumab for Retinal Vein Occlusion Associated with Macular Oedema. Noma H; Mimura T; Yasuda K; Shimura M Ophthalmic Res; 2016; 56(4):207-214. PubMed ID: 27160159 [TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion. Lim JW Ophthalmologica; 2011; 225(3):150-4. PubMed ID: 21150231 [TBL] [Abstract][Full Text] [Related]
8. Soluble vascular endothelial growth factor receptor-2 and inflammatory factors in macular edema with branch retinal vein occlusion. Noma H; Funatsu H; Mimura T; Eguchi S; Hori S Am J Ophthalmol; 2011 Oct; 152(4):669-677.e1. PubMed ID: 21726846 [TBL] [Abstract][Full Text] [Related]
9. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Funk M; Kriechbaum K; Prager F; Benesch T; Georgopoulos M; Zlabinger GJ; Schmidt-Erfurth U Invest Ophthalmol Vis Sci; 2009 Mar; 50(3):1025-32. PubMed ID: 19060280 [TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Noma H; Funatsu H; Yamasaki M; Tsukamoto H; Mimura T; Sone T; Jian K; Sakamoto I; Nakano K; Yamashita H; Minamoto A; Mishima HK Am J Ophthalmol; 2005 Aug; 140(2):256-61. PubMed ID: 16086947 [TBL] [Abstract][Full Text] [Related]
11. Changes in aqueous cytokines after intravitreal triamcinolone versus bevacizumab for macular oedema in branch retinal vein occlusion. Sohn HJ; Han DH; Lee DY; Nam DH Acta Ophthalmol; 2014 May; 92(3):e217-24. PubMed ID: 23889803 [TBL] [Abstract][Full Text] [Related]